Unapproved New Drugs/Misbranded: FDA Warning Letter to All Ketamine HCL / www.allketaminehcl.com, 2026-06-23
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
The FDA's Center for Drug Evaluation and Research issued a warning letter (MARCS-CMS 725150) to All Ketamine HCL on June 23, 2026, identifying violations at www.allketaminehcl.com involving unapproved and misbranded ketamine products sold in interstate commerce, including "Ketamax 50mg" marketed as an anesthetic for surgery and medical procedures. The FDA stated these products violate sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act, noting risks from unapproved drugs lacking FDA oversight safeguards and particular dangers from injectable formulations used without medical supervision. The agency requested immediate cessation of unapproved drug sales and warned that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: All Ketamine HCL
**Company and Violations**
All Ketamine HCL, operating at www.allketaminehcl.com, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on June 23, 2026. The agency documented violations following a website review on February 27, 2026. The FDA found that the company was introducing unapproved and misbranded ketamine drug products into interstate commerce, including products marketed under names such as "Ketamax 50mg" that were positioned as anesthetic medications. The agency emphasized particular concern about injectable ketamine products sold without medical supervision, citing risks of serious adverse events including sepsis and infection.
**Regulatory Citations and Implications**
The warning cites violations of the Federal Food, Drug, and Cosmetic Act sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a). Section 505(a) requires FDA approval before introducing new drugs into commerce; section 502(f)(1) mandates adequate directions for use on drug labeling; and section 503(b)(1) restricts prescription drugs to licensed practitioner supervision. These violations indicate the company distributed products without premarket approval and without requiring valid prescriptions. The FDA specifically noted that while FDA-approved ketamine formulations (KETALAR) and esketamine (SPRAVATO) exist, they carry significant restrictions including boxed warnings and mandatory REMS programs requiring supervised administration.
**Compliance Watch Points**
Companies in pharmaceutical distribution should monitor whether All Ketamine HCL responds substantively to the warning. The FDA explicitly warned of potential seizure and injunction actions if violations are not addressed. Industry observers typically track cessation of online sales, removal of product claims, and whether the company pursues legitimate regulatory pathways or ceases operations. The letter's emphasis on internet-based unapproved drug distribution suggests heightened FDA scrutiny of online pharmaceutical sales channels.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER All Ketamine HCL / www.allketaminehcl.com MARCS-CMS 725150 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: All Ketamine HCL / www.allketaminehcl.com United States support@allketaminehcl.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725150 To All Ketamine HCL: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.allketaminehcl.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.allketaminehcl.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.allketaminehcl.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.allketaminehcl.com, FDA Establishment Identifier (FEI) 3043544156, on February 27, 2026. Violations of the Federal Food, Drug, and Cosm…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has All Ketamine HCL / www.allketaminehcl.com had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for All Ketamine HCL / www.allketaminehcl.com as of 2026-07-07. Argus ingests new FDA enforcement records daily.
- What FDA violations was All Ketamine HCL / www.allketaminehcl.com cited for?
- The FDA Warning Letter to All Ketamine HCL / www.allketaminehcl.com (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
- When did FDA issue the warning letter to All Ketamine HCL / www.allketaminehcl.com?
- FDA issued the letter (MARCS-CMS 725150) on 2026-06-23 and posted it publicly on fda.gov on 2026-07-07.
- Is the FDA warning letter to All Ketamine HCL / www.allketaminehcl.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/all-ketamine-hcl-wwwallketaminehclcom-725150-06232026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Unapproved New Drugs/Misbranded: FDA Warning Letter to All Ketamine HCL / www.allketaminehcl.com, 2026-06-23. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-all-ketamine-hcl-www-allketaminehcl-com-2026-06-23-unapproved-drug
"Unapproved New Drugs/Misbranded: FDA Warning Letter to All Ketamine HCL / www.allketaminehcl.com, 2026-06-23." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-all-ketamine-hcl-www-allketaminehcl-com-2026-06-23-unapproved-drug.
Argus HQ Research. "Unapproved New Drugs/Misbranded: FDA Warning Letter to All Ketamine HCL / www.allketaminehcl.com, 2026-06-23." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-all-ketamine-hcl-www-allketaminehcl-com-2026-06-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_all_ketamine_hcl_www_allketaminehcl_com_2026_06_23_unapproved_drug_2026,
title = {Unapproved New Drugs/Misbranded: FDA Warning Letter to All Ketamine HCL / www.allketaminehcl.com, 2026-06-23},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-all-ketamine-hcl-www-allketaminehcl-com-2026-06-23-unapproved-drug},
note = {Accessed: July 13, 2026}
}